drug · small molecule
sotagliflozin
Marketedupdated 2mo agoby $LXRX LEXICON PHARMACEUTICALS, INC.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 6 investigational indications.
targets
Sodium/glucose cotransporter 1Sodium/glucose cotransporter 2
all catalysts(0)
nothing on the calendar yet
Trials studying sotagliflozin
- phase2Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
- phase3Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
- phase3A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
- phase3CKM For Safe Use of SGLT2i in Type 1 Diabetes
- EP1Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
- phase2Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 4, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Oct 7, 2030compositionUS 82171564.2y
- Oct 7, 2030compositionUS 82171564.2y
- May 29, 2028compositionUS 84764131.8y
- May 29, 2028compositionUS 84764131.8y
- May 4, 2028compositionUS 77815771.8y
- May 4, 2028compositionUS 77815771.8y
FDA exclusivities (2)
- May 26, 2028NCENew Chemical Entity (5y)1.8y
- May 26, 2028NCENew Chemical Entity (5y)1.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that